Ezetimibe reduces the small intestinal enterocyte uptake and absorption of cholesterol by binding to Niemann-Pick C1 Like 1 (NPC1L1), which keeps. J Lipid Res. Oct;53(10) Epub Jul Ezetimibe blocks the internalization of NPC1L1 and cholesterol in mouse small intestine. Xie C(1). Proc Natl Acad Sci U S A. Jun 7;(23) Epub May The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Garcia-Calvo M(1).
The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of. Ezetimibe is a potent inhibitor of cholesterol absorption that has been approved for the treatment of hypercholesterolemia, but its molecular Abstract - Methods - Results and Discussion. Ezetimibe is a drug that lowers plasma cholesterol levels. It acts by decreasing cholesterol it appears that ezetimibe blocks the critical mediator of cholesterol absorption, the Niemann-Pick C1-like 1 (NPC1L1) protein on the gastrointestinal .
Niemann-Pick C1-Like 1 (NPC1L1) is a gene associated with NPC1, mutation of which results The drug ezetimibe blocks the NPC1L1 causing a reduction in cholesterol absorption, resulting in a blood cholesterol reduction of between. The Niemann-Pick C1 Like 1 (NPC1L1) Inhibitor Ezetimibe Improves Metabolic Disease Via Decreased Liver X Receptor (LXR) Activity in Liver of Obese Male. Recent studies showed that ezetimibe blocks the internalization of NPC1L1, thus inhibiting cholesterol absorption. Further, Weingless and his group mapped. Niemann-Pick C1-like 1 (NPC1L1) is a target for ezetimibe, a drug that blocks intestinal cholesterol absorption. A new study by Ge et al. ().